Integrin α1β1 expression is controlled by c-MYC in colorectal cancer cells

Oncogene

Volumn 35, Issue 13, 2016, Pages 1671-1678

  Boudjadi, S ^a,b   Carrier, J C ^a,b   Groulx, J F ^a   Beaulieu, J F ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; MYC PROTEIN; SHORT HAIRPIN RNA; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 1;

ARTICLE; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOCARCINOMA; COLORECTAL CANCER CELL LINE; COMPUTER MODEL; CONTROLLED STUDY; DNA METHYLATION; DNA RESPONSIVE ELEMENT; DOWN REGULATION; EMBRYO; GENETIC TRANSFECTION; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CRYPT; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION; CACO-2 CELL LINE; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CACO-2 CELLS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; INTEGRIN ALPHA1BETA1; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84932160692     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.231     Document Type: Article

References (57)

1. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res 2010; 339: 269-280.
2. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007; 8: 215.
3. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11: 288-300.
4. Giancotti FG. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 1997; 9: 691-700.
5. Beausejour M, Noel D, Thibodeau S, Bouchard V, Harnois C, Beaulieu JF et al. Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes. Apoptosis 2012; 17: 566-578.
6. Vachon PH. Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct 2011; 2011: 738137.
7. Giancotti FG. Complexity and specificity of integrin signalling. Nat Cell Biol 2000; 2: E13-E14.
8. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998; 94: 625-634.
9. Abair TD, Bulus N, Borza C, Sundaramoorthy M, Zent R, Pozzi A. Functional analysis of the cytoplasmic domain of the integrin {alpha}1 subunit in endothelial cells. Blood 2008; 112: 3242-3254.
10. Lochter A, Navre M, Werb Z, Bissell MJ. alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol Biol Cell 1999; 10: 271-282.
11. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res 2003; 63: 8312-8317.
12. Macias-Perez I, Borza C, Chen X, Yan X, Ibanez R, Mernaugh G et al. Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer Res 2008; 68: 6127-6135.
13. Van Slambrouck S, Grijelmo C, De Wever O, Bruyneel E, Emami S, Gespach C et al. Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol 2007; 31: 1501-1508.
14. Boudjadi S, Carrier JC, Beaulieu JF. Integrin alpha1 subunit is up-regulated in colorectal cancer. Biomark Res 2013; 1: 16.
15. Obata H, Hayashi K, Nishida W, Momiyama T, Uchida A, Ochi T et al. Smooth muscle cell phenotype-dependent transcriptional regulation of the alpha1 integrin gene. J Biol Chem 1997; 272: 26643-26651.
16. Cheli Y, Kanaji S, Jacquelin B, Chang M, Nugent DJ, Kunicki TJ. Transcriptional and epigenetic regulation of the integrin collagen receptor locus ITGA1-PELO-ITGA2. Biochim Biophys Acta 2007; 1769: 546-558.
17. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J et al. c-myc oncogene expression in colorectal cancer. Cancer 1987; 59: 1289-1295.
18. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 1985; 5: 1969-1976.
19. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
20. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
21. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 2014; 511: 488-492.
22. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010; 31: 342-349.
23. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17: 1115-1129.
24. Yang H, Li TW, Ko KS, Xia M, Lu SC. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Hepatology 2009; 49: 860-870.
25. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993; 72: 211-222.
26. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000; 16: 653-699.
27. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211-1217.
28. Beaulieu JF. Differential expression of the VLA family of integrins along the crypt-villus axis in the human small intestine. J Cell Sci 1992; 102: 427-436.
29. Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, Berger DH. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia 2010; 12: 856-865.
30. Nishida W, Nakamura M, Mori S, Takahashi M, Ohkawa Y, Tadokoro S et al. A triad of serum response factor and the GATA and NK families governs the transcription of smooth and cardiac muscle genes. J Biol Chem 2002; 277: 7308-7317.
31. Tanaka N, Fukuzawa M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int J Oncol 2008; 33: 815-821.
32. Bettess MD, Dubois N, Murphy MJ, Dubey C, Roger C, Robine S et al. c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 2005; 25: 7868-7878.
33. Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2006; 34: 1480-1489.
34. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 2007; 18: 161-170.
35. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA 2006; 103: 6344-6349.
36. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003; 22: 6151-6159.
37. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-8169.
38. van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 2003; 22: 2664-2673.
39. Ni H, Dydensborg AB, Herring FE, Basora N, Gagne D, Vachon PH et al. Upregulation of a functional form of the beta4 integrin subunit in colorectal cancers correlates with c-Myc expression. Oncogene 2005; 24: 6820-6829.
40. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA et al. A high-resolution map of active promoters in the human genome. Nature 2005; 436: 876-880.
41. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007; 130: 77-88.
42. Hurlin PJ, Queva C, Eisenman RN. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 1997; 11: 44-58.
43. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequencespecific DNA binding by the c-Myc protein. Science 1990; 250: 1149-1151.
44. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002; 84: 81-154.
45. Chen Y, Xu J, Borowicz S, Collins C, Huo D, Olopade OI. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer 2011; 11: 246.
46. Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR. Regulation of c-myc expression by Ras/Raf signalling. Oncogene 1998; 16: 211-216.
47. Dydensborg AB, Teller IC, Groulx JF, Basora N, Pare F, Herring E et al. Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity. BMC Cancer 2009; 9: 223.
48. Benoit YD, Larrivee JF, Groulx JF, Stankova J, Vachon PH, Beaulieu JF. Integrin alpha8beta1 confers anoikis susceptibility to human intestinal epithelial crypt cells. Biochem Biophys Res Commun 2010; 399: 434-439.
49. Basora N, Desloges N, Chang Q, Bouatrouss Y, Gosselin J, Poisson J et al. Expression of the alpha9beta1 integrin in human colonic epithelial cells: resurgence of the fetal phenotype in a subset of colon cancers and adenocarcinoma cell lines. Int J Cancer 1998; 75: 738-743.
50. Groulx JF, Giroux V, Beausejour M, Boudjadi S, Basora N, Carrier JC et al. Integrin alpha6A splice variant regulates proliferation and the Wnt/beta-catenin pathway in human colorectal cancer cells. Carcinogenesis 2014; 35: 1217-1227.
51. Fujimoto H, Tanaka Y, Liu ZJ, Yagita H, Okumura K, Kosugi A et al. Downregulation of alpha6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. Genes Cells 2001; 6: 337-343.
52. Beaulieu JF. Integrin alpha6beta4 in colorectal cancer. World J Gastrointest Pathophysiol 2010; 1: 3-11.
53. Boudjadi S, Bernatchez G, Beaulieu JF, Carrier JC. Control of the human osteopontin promoter by ERRalpha in colorectal cancer. Am J Pathol 2013; 183: 266-276.
54. Dydensborg AB, Herring E, Auclair J, Tremblay E, Beaulieu JF. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1067-G1074.
55. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
56. Bustin SA, Beaulieu JF, Huggett J, Jaggi R, Kibenge FS, Olsvik PA et al. MIQE precis: practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. BMC Mol Biol 2010; 11: 74.
57. Park S, Chung S, Kim KM, Jung KC, Park C, Hahm ER et al. Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding. Biochim Biophys Acta 2004; 1670: 217-228.